tirzepatide nash phase 3 Effect of Tirzepatide Treatment on Hepatic Biomarkers in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease and Type 2 Diabetes Mellitus - Arai - 2025 Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis

Thompson, J., Diab, H., Datta, P., & Krutsch, K

(54) found that administering GIPR antagonist to healthy humans reduced postprandial insulin secretion and increased glucose excursions more than administering GLP-1R antagonist (GLP-1RA), indicating that endogenous GIP may play a more significant role in stimulating insulin secretion and reducing postprandial plasma glucose excursions compared to endogenous GLP-1

Change eating habits When and how you eat can make a big difference in managing side effects like semaglutide heartburn

In this context, it is interesting that variants in BDNF have been linked to altered eating behavior and dietary intake [111112]

The platform works with CareGLP, which employs Beluga Health as the prescribing clinical group